Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTX-011 for Postoperative Analgesia in Pediatric Inguinal Herniorrhaphy
NCT03922048Phase 2Withdrawn
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Jul 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine + meloxicam in postoperative pain (10 cohorts), sponsored by Heron Therapeutics, Inc. Primary endpoints: Area under the concentration-time curve from Time 0 extrapolated to infinity at 72 hours, Maximum concentration at 72 hours and 1 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
bupivacaine + meloxicam
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03922048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922048.